证券代码：002524 证券简称：光正眼科 公告编号：2025-045 光正眼科医院集团股份有限公司 关于下属子公司综合授信及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 光正眼科医院集团股份有限公司 截至本公告披露日，光正眼科医院集团股份有限公司（以下简称"公司"） 及控股子公司对外担保总额超过最近一期经审计（归母）净资产 100%，均为公 司、控股子公司、全资子公司及其下属公司间互相担保。敬请投资者关注担保风 险。 一、概述 公司于 2025 年 4 月 22 日召开第六届董事会第二次会议和第六届监事会第二 次会议，分别审议通过了《关于 2025 年度向银行等相关金融机构申请综合授信 额度并提供担保的议案》，同意根据公司 2025 年度生产经营计划和发展规划， 为保证公司正常经营的资金需求，公司、公司合并报表范围内的下属控股子公司 及孙公司（简称"控股子公司"）2025 年度拟将向银行等相关金融机构申请总 额不超过 6.5 亿元的综合授信（包括但不限于：信用贷款、第三方担保贷款、资 产抵押贷款、银行承兑汇票、银行保函、保理 ...

Group 1 - The core business of the company is focused on investment and management of ophthalmology hospitals, with main products including refractive projects, cataract projects, vision care services, and steel structure manufacturing and installation [1] - As of March 31, 2025, the number of shareholders for the company increased to 47,404, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 208 million yuan, a year-on-year increase of 4.32%, and a net profit of 573,800 yuan, a year-on-year increase of 103.06%, with a gross profit margin of 37.61% [1] Group 2 - The company's price-to-earnings (PE) ratio (TTM) is -14.05, and the price-to-book (PB) ratio is 19.13, with a total market capitalization of 2.183 billion yuan [2] - The industry average PE ratio is 38.66, while the industry median is 43.32, indicating that the company is significantly below the industry average in terms of valuation metrics [2] - Comparatively, other companies in the industry have varying PE ratios, with some companies like RunDa Medical showing a PE ratio of -296.69, indicating a wide range of performance and valuation within the sector [2]

一、 会议召开情况 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-044 光正眼科医院集团股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会没有被否决议案的情形，没有增加或变更提案。 2.本次股东大会不涉及变更前次股东大会决议。 1.会议召开的日期、时间： 现场会议时间为：2025 年 5 月 20 日（星期二）下午 15:00； 网络投票时间为：2025 年 5 月 20 日。其中：通过深圳证券交易所交易系统 进行网络投票的具体时间为 2025 年 5 月 20 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 5 月 20 日 9:15—15:00 期间的任意时间。 2.现场会议召开地点：光正眼科医院集团股份有限公司会议室（乌鲁木齐经 济技术开发区融合北路 266 号）； 3.会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式； 4.会议 ...

T&P 新疆天阳律师事务所 光正眼科 2024 年年度股东大会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 2024 年年度股东大会 法律意见书 天阳证股字[2025]第 18 号 新疆天阳律师事务所 二○二五年五月 1 T&P 新疆天阳律师事务所 光正眼科 2024 年年度股东大会 新疆天阳律师事务所 关于光正眼科医院集团股份有限公司 2024 年年度股东大会 法律意见书 天阳证股字[2025]第 18 号 致：光正眼科医院集团股份有限公司 新疆天阳律师事务所（下称"本所"）接受光正眼科医院集团股份有限公司 （下称"公司"）的委托，委派本所李大明律师、邵丽娅律师出席公司 2024 年 年度股东大会，根据《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司股东会规则》和《光 正眼科医院集团股份有限公司章程》（下称"《公司章程》"），按照律师行业 公认的业务标准、道德规范和勤勉尽责精神，对有关的文件和事实进行核查与验 证，并出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的文件材料进行了核查验 证。在进行核查验证过程中，公司已向本所保证 ...

Group 1 - The core business of the company is focused on investment and management of ophthalmology hospitals, with main products including refractive projects, cataract projects, vision care services, and steel structure manufacturing and installation [1] - As of the first quarter of 2025, the company reported revenue of 208 million yuan, a year-on-year increase of 4.32%, and a net profit of 573,800 yuan, a year-on-year increase of 103.06%, with a gross profit margin of 37.61% [1] - The company's stock closed at 4.24 yuan, up 2.17%, with a latest price-to-book ratio of 19.27, marking a new low in 40 days, and a total market capitalization of 2.198 billion yuan [1] Group 2 - The company has three institutional investors holding a total of 137.3928 million shares, with a total market value of 541 million yuan [1] - The company's price-to-earnings ratio (TTM) is -14.15, while the industry average is 38.49, indicating a significant disparity [2] - The company's market capitalization stands at 2.198 billion yuan, compared to the industry median of 5.270 billion yuan [2]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-043 光正眼科医院集团股份有限公司 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 23 日（周五） 15:00-17:30。届时 公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与！ 特此公告。 光正眼科医院集团股份有限公司董事会 二〇二五年五月十六日 关于参加 2025 年新疆辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，光正眼科医院集团股份有限公司（以下 简称"公司"）将参加由新疆上市公司协会根据新疆证监局工作部署，联合深圳 市全景网络有限公司举办的"2025 年新疆辖区上市公司投资者网上集体接待日 活动"，现将相关事项公 ...

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 关于举办 2024 年度业绩网上说明会的公告 光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-042 光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司（以下简称"公司"）将于 2025 年 5 月 19 日（星期一）下午 15:30—16:30，举办 2024 年年度报告网上说明会，与广大股 东和投资者对公司发展战略、经营情况等进行沟通和交流。本次年度业绩说明会 将 采 用 网 络 远 程 的 方 式 举 行 ， 投 资 者 可 登 陆 深 交 所 成 长 通 平 台 （https://list.cninfo.com.cn）参与本次年度业绩说明会。 光正眼科医院集团股份有限公司董事会 二〇二五年五月十四日 参加本次业绩说明会的有：公司董事长、总经理兼董秘周永麟先生，独立董 事郑石桥先生,董事兼财务总监李俊英女士，证券事务代表雒萍女士。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议 ...

Core Insights - The company reported a revenue of 208 million yuan and a net profit attributable to shareholders of 573,800 yuan for Q1 2025, marking a turnaround with a 103.06% improvement compared to the same period last year [1] - The company is focusing on high-end cataract and refractive surgery, transitioning from basic cataract surgeries to advanced refractive cataract surgeries to meet the increasing quality demands of middle-aged and elderly patients [1][2] - The refractive and cataract projects remain the core business, generating revenues of 258 million yuan and 288 million yuan respectively, accounting for 61.15% of total revenue, with gross margins of 43.86% and 49.87% [1] Business Strategy - The company is deepening its integrated development strategy in medical education, research, and services, collaborating with Fudan University and Jiangnan University to enhance research capabilities and innovation in eye health [2] - The company aims to implement a core strategy focused on "eye care medical business" and "smart hospital construction," emphasizing the integration of AI in services and management [2] - Future growth is expected to rely on technological upgrades, digital innovation, and resource integration to overcome profitability challenges and achieve high-quality growth in a competitive market [2]

Financial Performance - The company reported a basic earnings per share of 0.0000 yuan for Q1 2025, a significant improvement from -0.0400 yuan in Q1 2024, marking a 100% increase [1] - Net profit for Q1 2025 was 0.01 billion yuan, compared to a loss of 0.19 billion yuan in Q1 2024, representing a 105.26% increase [1] - Operating revenue for Q1 2025 was 2.08 billion yuan, up 4% from 2 billion yuan in Q1 2024 [1] - The return on equity (ROE) improved to 0.50% in Q1 2025 from -6.84% in Q1 2024, indicating a 107.31% increase [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,177.04 million shares, accounting for 29.87% of the circulating shares, with a slight increase of 9.92 million shares from the previous period [1] - The largest shareholder, Guangzheng Investment Co., Ltd., holds 12,916.87 million shares, representing 25.41% of the total share capital, with no change in holdings [2] - New entrants among the top shareholders include Lin Yande, Hao Caiming, and Hao Chengxiang, while Xun Yanhong, Qiu Wanshu, and Luo Wenhua have exited the top ten list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]